Spexis AG, the Swiss biotech that was only created at the end of last year through the merger of troubled Polyphor AG and EnBiotix, is already facing an uncertain future as it battles for funds to survive.
Future For Spexis Looks Far From Secure
Swiss Biotech Launched End of 2021
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
